GO:0036458 hepatocyte growth factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036458 (hepatocyte growth factor binding) is a molecular function describing the selective interaction of a protein or proteoglycan with hepatocyte growth factor (HGF), also known as scatter factor.
• HGF binding is mediated by heparan sulfate proteoglycans and the MET receptor tyrosine kinase, which together control HGF presentation, activation, and signaling.
• The HGF/MET axis is a central driver of cell proliferation, motility, and morphogenesis, and its dysregulation is implicated in cancer, liver failure, and tissue repair.
• HGF binding proteins include MET, heparan sulfate proteoglycans, and engineered HGF-binding peptides used for imaging and therapy.
• Research on HGF binding relies on binding assays, surface plasmon resonance, PET imaging, and CRISPR-based models to dissect ligand-receptor interactions.
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, and library screening services to study HGF binding and its downstream biology.
Description
Hepatocyte growth factor (HGF), also known as scatter factor, is a pleiotropic growth factor that binds to heparan sulfate proteoglycans and the MET receptor tyrosine kinase to regulate cell proliferation, motility, and morphogenesis. The Gene Ontology molecular function term GO:0036458, hepatocyte growth factor binding, captures the selective interaction of a protein or proteoglycan with HGF, a critical step in HGF presentation, activation, and signaling. This term is essential for annotating gene products that directly bind HGF, including the MET receptor, heparan sulfate proteoglycans, and engineered HGF-binding peptides. Understanding HGF binding is important because the HGF/MET pathway is frequently dysregulated in human diseases, including cancer, acute-on-chronic liver failure, and tissue injury. HGF binding proteins modulate ligand availability, receptor activation, and downstream signaling, making them attractive targets for therapeutic intervention and diagnostic imaging. Researchers studying HGF binding need robust experimental models to determine whether candidate genes are causally involved in HGF-dependent processes. This article provides a research-grade overview of GO:0036458, covering its definition, biological significance, key genes, regulatory mechanisms, disease links, and experimental methods. All statements are supported by published literature, and the content is optimized for both human readers and generative AI retrieval.
hepatocyte growth factor binding At A Glance
| GO ID | GO:0036458 |
|---|---|
| GO term | hepatocyte growth factor binding |
| Ontology | molecular_function |
| Synonym | HGF binding |
| Major function | Binding to hepatocyte growth factor (HGF), mediating its presentation, sequestration, or signaling activation |
| Major ligands | HGF (scatter factor), a heparan sulfate-binding pleiotropic growth factor |
| Major receptors | MET receptor tyrosine kinase, heparan sulfate proteoglycans |
| Related diseases | Cancer, acute-on-chronic liver failure, tissue injury |
| Research methods | Binding assays, surface plasmon resonance, PET imaging, CRISPR models |
What Is GO:0036458?
GO:0036458, hepatocyte growth factor binding, is defined as the binding to a hepatocyte growth factor. In practice, this molecular function describes the physical interaction between a protein or proteoglycan and HGF, a secreted growth factor that regulates cell growth, motility, and morphogenesis. This binding event is essential for HGF sequestration, presentation to the MET receptor, and subsequent signal transduction.
Why Is hepatocyte growth factor binding Important in Cell Biology?
HGF binding is a critical molecular function because it controls the bioavailability and activity of HGF, a growth factor that regulates cell proliferation, survival, motility, and morphogenesis. Dysregulated HGF binding contributes to cancer progression, liver failure, and impaired tissue repair, making it a key target for therapeutic development and diagnostic imaging.
• HGF binding regulates the activation of the MET receptor tyrosine kinase, a major oncogenic driver in many cancers.
• Heparan sulfate proteoglycans bind HGF and modulate its presentation to MET, influencing signaling specificity.
• Dysregulated HGF binding is implicated in acute-on-chronic liver failure through the Angiopoietin-2-HGF-C/EBPβ pathway.
• HGF binding proteins are targets for cancer therapy, including inhibitors of the HGF/MET axis.
• Engineered HGF-binding peptides are used for PET imaging of tumors, enabling non-invasive detection.
• HGF binding is essential for tissue regeneration and wound healing, making it relevant to regenerative medicine.
• Computational studies of HGF receptor-ligand interactions aid in identifying novel therapeutic inhibitors.
• HGF binding assays are used to screen for modulators of the HGF/MET pathway.
• CRISPR-based models allow functional dissection of genes involved in HGF binding.
• Understanding HGF binding supports the development of targeted therapies for liver disease and cancer.
Molecular Mechanism of hepatocyte growth factor binding
HGF Structure and Heparan Sulfate Binding
In simple terms: HGF is a growth factor that sticks to sugar chains on the cell surface, which helps it work properly.
HGF is a heparan sulfate-binding pleiotropic growth factor, meaning it interacts with heparan sulfate proteoglycans on the cell surface and in the extracellular matrix. This binding is mediated by specific domains in HGF and is essential for its biological activity, including presentation to the MET receptor. Heparan sulfate binding also protects HGF from degradation and modulates its signaling range.
Interaction with the MET Receptor
In simple terms: HGF binds to a receptor called MET on the cell surface, which turns on signals that tell cells to grow and move.
The MET receptor tyrosine kinase is the primary signaling receptor for HGF. HGF binding to MET induces receptor dimerization, autophosphorylation, and activation of downstream signaling pathways, including PI3K/AKT and MAPK. This interaction is critical for cell proliferation, survival, and migration.
Heparan Sulfate Proteoglycans as Co-receptors
In simple terms: Sugar-protein molecules on the cell surface help HGF find and activate its receptor.
Heparan sulfate proteoglycans act as co-receptors for HGF, facilitating its binding to MET and enhancing signaling. These proteoglycans can also sequester HGF, creating gradients that guide cell migration. The interplay between HGF, heparan sulfate, and MET determines the specificity and intensity of downstream responses.
Engineered HGF-Binding Peptides
In simple terms: Scientists have made small molecules that can grab HGF, which can be used to image tumors or block signaling.
Nonstandard macrocyclic peptides, such as HiP-8, have been developed to specifically bind two-chain mature HGF. These peptides can be labeled with radionuclides for positron emission tomography (PET) imaging of tumors, enabling non-invasive detection of HGF expression. Such engineered binders are valuable tools for studying HGF biology and for therapeutic targeting.
Computational Modeling of HGF Binding
In simple terms: Computer simulations help researchers understand how HGF fits into its receptor and find drugs that can block it.
Computational investigation of HGF receptor-ligand interactions has identified novel therapeutic inhibitors by modeling the binding interface. These studies provide structural insights into the molecular determinants of HGF binding and guide the design of small molecules or peptides that modulate the HGF/MET pathway.
Key Genes Involved in GO:0036458 hepatocyte growth factor binding
The following genes and proteins are directly involved in hepatocyte growth factor binding or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HGF | Ligand that binds heparan sulfate and MET; pleiotropic growth factor | Central to HGF binding studies; target for cancer and liver disease |
| MET | Receptor tyrosine kinase that binds HGF and transduces signals | Major oncogene; target for inhibitors and CRISPR models |
| HSPG2 | Heparan sulfate proteoglycan that binds HGF and modulates signaling | Co-receptor for HGF; affects ligand presentation |
| SDC1 | Syndecan-1, a heparan sulfate proteoglycan that can bind HGF | Cell surface co-receptor; impacts HGF signaling |
| GPC1 | Glypican-1, a heparan sulfate proteoglycan with HGF-binding potential | Modulates growth factor availability |
| ANGPT2 | Angiopoietin-2, regulates HGF expression in liver failure | Linked to acute-on-chronic liver failure via HGF pathway |
| CEBPB | C/EBPβ transcription factor downstream of HGF signaling | Mediates HGF effects in liver disease |
| HiP-8 | Engineered macrocyclic peptide that binds two-chain mature HGF | Used for PET imaging of tumors |
| HGFAC | HGF activator, cleaves pro-HGF to mature HGF | Regulates HGF bioavailability |
| ST14 | Matriptase, activates pro-HGF and modulates HGF binding | Protease involved in HGF activation |
| PLAU | Urokinase, contributes to HGF activation cascade | Indirect regulator of HGF binding |
| PLAT | Tissue plasminogen activator, involved in HGF activation | Modulates HGF proteolysis |
| NRP1 | Neuropilin-1, can bind HGF and enhance MET signaling | Co-receptor for HGF |
| CD44 | Cell surface glycoprotein that can interact with HGF | Modulates HGF presentation |
| ITGB1 | Integrin beta-1, cooperates with MET signaling | Downstream of HGF binding |
| GAB1 | Docking protein downstream of MET | Mediates HGF-induced signaling |
| GRB2 | Adaptor protein in MET signaling | Links HGF binding to MAPK pathway |
| STAT3 | Transcription factor activated by HGF/MET | Mediates gene expression changes |
How Is hepatocyte growth factor binding Regulated?
HGF binding is regulated at multiple levels, including proteolytic activation of pro-HGF by proteases such as HGF activator (HGFAC) and matriptase (ST14). Heparan sulfate proteoglycans modulate HGF binding by acting as co-receptors or sequestering agents. The expression of HGF and MET is controlled by transcription factors, including C/EBPβ, which is involved in sepsis-induced liver failure through the Angiopoietin-2-HGF-C/EBPβ pathway. Additionally, quercetin has been shown to induce HGF production, suggesting dietary or pharmacological regulation.
hepatocyte growth factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MET | Cancer, liver disease | MET knockout or point-mutation cell lines |
| HGF | Acute-on-chronic liver failure, tissue repair | HGF overexpression or knockout models |
| ANGPT2 | Sepsis-induced liver failure | ANGPT2 knockout in endothelial cells |
| CEBPB | Liver failure, inflammation | CEBPB knockout or knock-in |
| HSPG2 | Cancer, tissue repair | HSPG2 knockout or point mutation |
Cancer
Dysregulated HGF binding and MET activation are hallmarks of many cancers, promoting tumor growth, invasion, and metastasis. Targeting the HGF/MET pathway with inhibitors or HGF-binding peptides is a promising therapeutic strategy. PET imaging using HGF-binding peptides like HiP-8 enables non-invasive detection of HGF-expressing tumors.
Liver Disease
Sepsis-induced endothelial dysfunction drives acute-on-chronic liver failure through the Angiopoietin-2-HGF-C/EBPβ pathway, highlighting the role of HGF binding and signaling in liver pathology. HGF is also critical for liver regeneration, and its binding to MET and heparan sulfate proteoglycans is essential for hepatocyte proliferation.
Tissue Repair and Regeneration
HGF binding to MET and heparan sulfate proteoglycans is essential for tissue repair and regeneration, including wound healing and organ regeneration. Heparinized and HGF-coated acellular scaffolds have been developed to promote vascular regeneration, demonstrating the therapeutic potential of HGF binding.
From hepatocyte growth factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MET mediate HGF binding and signaling? | MET knockout cell lines |
| What is the role of heparan sulfate in HGF binding? | HSPG2 or SDC1 knockout cells |
| Can HGF binding be blocked therapeutically? | Point mutations in HGF or MET binding interface |
| How does HGF binding affect liver failure? | ANGPT2 or CEBPB knockout mouse models |
| Can HGF binding be visualized in tumors? | HiP-8 PET imaging in xenograft models |
| Does quercetin induce HGF production? | HGF overexpression or reporter assays |
How to Study the hepatocyte growth factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | HGF-MET interaction studies |
| ELISA | Protein-protein binding | Quantifying HGF binding |
| PET imaging | In vivo HGF expression | Tumor imaging with HiP-8 |
| CRISPR screening | Gene function in HGF binding | Identifying novel regulators |
| Molecular docking | Binding interface prediction | Inhibitor design |
| Western blot | Protein expression and phosphorylation | MET activation |
| Immunoprecipitation | Protein complexes | HGF-binding partner identification |
| Cell migration assay | Functional response to HGF | Scatter factor activity |
Binding Assays
Surface plasmon resonance (SPR) and enzyme-linked immunosorbent assays (ELISA) are used to measure HGF binding affinity and kinetics. These methods quantify interactions between HGF and its binding partners, including MET and heparan sulfate proteoglycans.
PET Imaging
Positron emission tomography (PET) using radiolabeled HGF-binding peptides, such as 64Cu-labeled HiP-8, enables non-invasive imaging of HGF expression in tumors. This method is valuable for diagnosing and monitoring HGF-dependent cancers.
CRISPR Screening
CRISPR library screening can identify genes that regulate HGF binding and MET signaling. This approach enables unbiased discovery of novel modulators of the HGF/MET pathway.
Computational Modeling
Molecular dynamics simulations and docking studies model HGF-receptor interactions to identify novel inhibitors. These computational methods complement experimental binding assays.
How CRISPR Can Be Used to Study GO:0036458 hepatocyte growth factor binding
Knockout
CRISPR knockout of MET or heparan sulfate proteoglycan genes (e.g., HSPG2) can abolish HGF binding and downstream signaling, providing causal evidence for their roles. Knockout models are essential for validating HGF-binding partners identified in screens.
Point Mutation
Point mutations in the HGF-binding interface of MET or in HGF itself can disrupt binding without affecting protein expression, allowing precise structure-function studies. These models help identify critical residues for HGF interaction.
Knock-in
Knock-in of tagged HGF or MET (e.g., GFP or luciferase) enables real-time tracking of HGF binding and trafficking in live cells. Tagged knock-in models are valuable for imaging and biochemical studies.
Overexpression
Overexpression of HGF or MET can enhance HGF binding and signaling, modeling cancer and tissue regeneration. Overexpression models are used to study gain-of-function effects and drug responses.
How EDITGENE Supports hepatocyte growth factor binding Research
Researchers studying hepatocyte growth factor binding-related genes often need to determine whether a candidate gene is causally involved in HGF binding, MET signaling, or downstream biological processes. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for hepatocyte growth factor binding research.
Frequently Asked Questions About hepatocyte growth factor binding
What is hepatocyte growth factor binding?
Hepatocyte growth factor binding (GO:0036458) is a molecular function describing the binding to hepatocyte growth factor (HGF), a pleiotropic growth factor that regulates cell growth, motility, and morphogenesis.
What genes are involved in hepatocyte growth factor binding?
Key genes include HGF, MET, heparan sulfate proteoglycans (e.g., HSPG2, SDC1), and proteases that activate HGF such as HGFAC and ST14.
What is the role of MET in HGF binding?
MET is the receptor tyrosine kinase that binds HGF, leading to receptor activation and downstream signaling that controls cell proliferation and survival.
How is HGF binding regulated?
HGF binding is regulated by proteolytic activation of pro-HGF, heparan sulfate proteoglycans, and transcription factors such as C/EBPβ.
What diseases are associated with HGF binding?
Dysregulated HGF binding is implicated in cancer, acute-on-chronic liver failure, and impaired tissue repair.
What methods are used to study HGF binding?
Common methods include surface plasmon resonance, ELISA, PET imaging, and CRISPR screening.
Can CRISPR be used to study HGF binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect HGF binding and signaling.
What is HiP-8 and how does it relate to HGF binding?
HiP-8 is a nonstandard macrocyclic peptide that specifically binds two-chain mature HGF and is used for PET imaging of tumors.
How does heparan sulfate affect HGF binding?
Heparan sulfate proteoglycans act as co-receptors for HGF, facilitating its binding to MET and modulating signaling.
What is the clinical significance of HGF binding?
HGF binding is a therapeutic target in cancer and liver disease, and HGF-binding peptides are used for diagnostic imaging.
Conclusion
GO:0036458, hepatocyte growth factor binding, is a critical molecular function that governs HGF bioavailability and signaling through MET and heparan sulfate proteoglycans. Its dysregulation contributes to cancer, liver failure, and impaired tissue repair, making it a key area of biomedical research. Advances in CRISPR models, binding assays, and imaging techniques continue to unravel the molecular details of HGF binding, offering new opportunities for therapeutic intervention. EDITGENE supports researchers in this field with comprehensive CRISPR services, from knockout and point mutation to knock-in, overexpression, and library screening, enabling precise functional studies of HGF binding and its downstream effects.
References
- 1. Elias G et al.. 2023. Sepsis-induced endothelial dysfunction drives acute-on-chronic liver failure through Angiopoietin-2-HGF-C/EBPβ pathway.. Hepatology 78(3):803-819 PMID: 36943063
- 2. Akimoto Y et al.. 2026. Induction of Hepatocyte Growth Factor Production by Quercetin.. Biol Pharm Bull 49(2):249-253 PMID: 41656086
- 3. Cheng J et al.. 2024. Development of heparinized and hepatocyte growth factor-coated acellular scaffolds using porcine carotid arteries.. J Biomed Mater Res B Appl Biomater 112(1):e35317 PMID: 37584376
- 4. Azmal M et al.. 2025. Computational investigation of hepatocyte growth factor receptor-ligand interactions for the identification of novel therapeutic inhibitors.. Comput Biol Med 198(Pt B):111250 PMID: 41138359
- 5. Lyon M et al.. 1994. Hepatocyte growth factor/scatter factor: a heparan sulphate-binding pleiotropic growth factor.. Biochem Soc Trans 22(2):365-70 PMID: 7958326
- 6. De Silva DM et al.. 2017. Targeting the hepatocyte growth factor/Met pathway in cancer.. Biochem Soc Trans 45(4):855-870 PMID: 28673936
- 8. Warashina S et al.. 2023. Two-Chain Mature Hepatocyte Growth Factor-Specific Positron Emission Tomography Imaging in Tumors Using (64)Cu-Labeled HiP-8, a Nonstandard Macrocyclic Peptide Probe.. Mol Pharm 20(4):2029-2038 PMID: 36862642
